Circ_0000396 Inhibits Rheumatoid Arthritis Synovial Fibroblast Growth and Inflammatory Response Via MiR-203/HBP1 Axis
Overview
Affiliations
Background: Circ_0000396 was found to be down-regulated in the rheumatoid arthritis (RA) patients and had a high diagnostic value. However, the function and mechanisms underlying circ_0000396 in RA progression remain unclear.
Methods: The expression of circ_0000396, microRNA (miR)-203 and HMG-box transcription factor 1 (HBP1) was detected using qRT-PCR and western blot. The proliferative and apoptotic capabilities of rheumatoid arthritis synovial fibroblasts (RASFs) were measured by colony formation, CCK-8, flow cytometry and western blot assays, respectively. The levels of interleukins (IL)-6, IL-1β, IL-8 and tumor necrosis factor-α (TNF-α) were detected using enzyme-linked immunosorbent assay (ELISA). The target correlations between miR-203 and circ_0000396 or HBP1 were validated using pull-down and dual-luciferase reporter assay.
Results: Circ_0000396 was decreased in RA synovial tissues and RASFs, and overexpression of circ_0000396 suppressed cell proliferation, induced cell apoptosis and reduced the release of inflammatory cytokine IL-6, IL-1β, IL-8 and TNF-α in RASFs, while circ_0000396 deletion functioned oppositely. MiR-203 was confirmed to be a target of circ_0000396, and miR-203 reversed the protective effects of circ_0000396 on the dysfunction and inflammation of RASFs. HBP1 was a target of miR-203, and silencing miR-203 inhibited RASFs malignant changes by regulating HBP1. In addition, circ_0000396 could regulate HBP1 by sponging miR-203, and HBP1 decrease attenuated the effects of circ_0000396 on RASF growth and inflammation.
Conclusion: Circ_0000396 inhibited the growth and inflammation in RASFs by regulating miR-203/HBP1 axis, providing a potential therapeutic target for RA.
Khokhar M, Dey S, Tomo S, Jaremko M, Emwas A, Pandey R ACS Pharmacol Transl Sci. 2024; 7(6):1664-1693.
PMID: 38898941 PMC: 11184612. DOI: 10.1021/acsptsci.4c00067.
Exosomes and exosomal miRNAs: A new avenue for the future treatment of rheumatoid arthritis.
Liu Y, Jiang P, Qu Y, Liu C, Zhang D, Xu B Heliyon. 2024; 10(6):e28127.
PMID: 38533025 PMC: 10963384. DOI: 10.1016/j.heliyon.2024.e28127.
Yu H, Yang J, Chen K, Kang W, Zhu F J Orthop Surg Res. 2023; 18(1):718.
PMID: 37737195 PMC: 10514958. DOI: 10.1186/s13018-023-04117-5.
Biomarkers (mRNAs and non-coding RNAs) for the diagnosis and prognosis of rheumatoid arthritis.
Jiang Y, Zhong S, He S, Weng J, Liu L, Ye Y Front Immunol. 2023; 14:1087925.
PMID: 36817438 PMC: 9929281. DOI: 10.3389/fimmu.2023.1087925.
Li Z, Wang J, Lin Y, Fang J, Xie K, Guan Z Front Pharmacol. 2022; 13:983744.
PMID: 36278188 PMC: 9585171. DOI: 10.3389/fphar.2022.983744.